Anthony Hunt - 12 Nov 2025 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Director
Signature
/s/ Jennifer Carmichael (Attorney in Fact)
Issuer symbol
RGEN
Transactions as of
12 Nov 2025
Net transactions value
-$3,075,190
Form type
4
Filing time
13 Nov 2025, 16:30:08 UTC
Previous filing
11 Sep 2025
Next filing
14 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hunt Anthony Director C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM /s/ Jennifer Carmichael (Attorney in Fact) 13 Nov 2025 0001606030

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Options Exercise $846,750 +25,000 +25% $33.87 125,743 12 Nov 2025 Direct
transaction RGEN Common Stock Sale $579,556 -3,741 -3% $154.92 122,002 12 Nov 2025 Direct F1, F2
transaction RGEN Common Stock Sale $738,729 -4,740 -3.9% $155.85 117,262 12 Nov 2025 Direct F1, F3
transaction RGEN Common Stock Sale $776,827 -4,959 -4.2% $156.65 112,303 12 Nov 2025 Direct F1, F4
transaction RGEN Common Stock Sale $1,753,279 -11,096 -9.9% $158.01 101,207 12 Nov 2025 Direct F1, F5
transaction RGEN Common Stock Sale $73,549 -464 -0.46% $158.51 100,743 12 Nov 2025 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Options Exercise $0 -25,000 -14% $0.000000 157,344 12 Nov 2025 Common Stock 25,000 $33.87 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024.
F2 $154.92 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.26 to $155.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 $155.85 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.28 to $156.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 $156.65 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.31 to $157.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 $158.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.41 to $158.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 $158.51 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.43 to $158.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027.